The Alzheimer's and Blood Glucose Levels Study is researching the differences in blood glucose levels between people with and without Mild Cognitive Impairment or Alzheimer's disease with the aim of early detection of Alzheimer's Disease.

This study will collect continuous glucose monitor (CGM) data from participants already using CGMs to better understand the relationship between Alzheimer's Disease and blood glucose levels. This study will use the " Endobits Companion " app for data collection. The Endobits Companion app is freely available for Android and iOS mobile devices, and was designed to keep track of patients diabetes management through a journal and relay this information with their CGM readings to their caring physician.

Inclusion Criteria:

• For the case group: have been diagnosed with MCI or AD within the past 5 years.
• For the control group: have not been diagnosed with MCI or AD or another major dementia disease
• Currently using a continuous glucose monitor (CGM).
• Willing and able to provide informed consent, and to have their data collected through the Endobits Companion app. If the participant themself is unable to provide informed consent, it will be sought from their primary caregiver.

Exclusion Criteria:

• Patients younger than 50 years of age.
• Patients with a BMI lower than 18 or higher than 35.
• Patients with a major psychiatric illness (e.g., major depressive disorder, schizophrenia, bipolar disorder)
• Patients diagnosed with another major dementia disease, including vascular dementia, Lewy Body disease, Huntington's disease, Creutzfeldt-Jakob disease, and Parkinson's disease.

The study population is drawn from older individuals (at least 50 years of age) with or without MCI or AD.